Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.

The Journal of biological chemistry - 25 Feb 2000

Gurnell M, Wentworth J M, Agostini M, Adams M, Collingwood T N, Provenzano C, Browne P O, Rajanayagam O, Burris T P, Schwabe J W, Lazar M A, Chatterjee V K

Abstract excerpt

The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) promotes adipocyte differentiation, exerts atherogenic and anti-inflammatory effects in monocyte/macrophages, and is believed to mediate the insulin-sensitizing action of antidiabetic thiazolidinedione ligands. As no complete PPARgamma antagonists have been described hitherto, we have constructed a dominant-negative mutant receptor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Adipocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Vectors

Share to Precipitin Tests

Share to Receptors, Cytoplasmic and Nuclear

Share to Rosiglitazone

Share to Thiazoles

Share to Thiazolidinediones

Source

Identifiers

PMID: 10681562
DOI: 10.1074/jbc.275.8.5754

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.PMID 10681562Read ↗

Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.Semantic proximity Read ↗

Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance.Semantic proximity Read ↗

A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus.Semantic proximity Read ↗

T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.Semantic proximity Read ↗

A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells.Semantic proximity Read ↗

Identification of a truncated alternative splicing variant of human PPARgamma1 that exhibits dominant negative activity.Semantic proximity Read ↗

Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-activated receptor-gamma mutations associated with diabetes.Semantic proximity Read ↗

Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review.Semantic proximity Read ↗

Peroxisome proliferator-activated receptor-gamma and insulin action: insights from human genetics.Semantic proximity Read ↗

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.Semantic proximity Read ↗

Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology.Semantic proximity Read ↗

PPAR gamma as a metabolic regulator: insights from genomics and pharmacology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.